Dr. David Samadi An Interview with the Most Successful Urologist in the World

Dr. David Samadi is the famous medical professional and the chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital located in New York. He is a specialized urologist and has years of experience in diagnosing urological diseases, prostate cancer, bladder cancer, kidney cancer and others. Over the years, he has successfully carried out thousands of non-invasive and minimal-invasive prostate cancer treatments, including the advanced laparoscopic robotic radical prostatectomy.

Dr. David Samadi completed his graduation from Stony Brook University and then obtained his M.D from the Stony Brook School of Medicine. He got his postgraduate training at the famous Montefiore Medical Center and also from Albert Einstein College of Medicine. He then went on to get a fellowship in proctology from Memorial Sloan Kettering Cancer Center and then started his robotic radical prostatectomy fellowship at Henri Mondor Hospital Creteil, France. He has performed surgeries in many different countries and is the most sought after urologist in the world.

In a recent interview with Ideamensch, Dr. David Samadi shared information about his current project that he working on. He is developing a new prostate removal technique called the Samadi Modified Advanced Robotic Technique that is going to help separate the prostate from the surrounding nerves so that there is no damage to these nerves that often results in serious side effects. He also works towards building an efficient operating room team that will help make surgeries easier than ever before. He has worked hard to make his hospital one of the only places in the world where a robot can perform up to five surgeries in a single day with more emphasis on efficiency rather than speed.

Dr. David Samadi considers his team at the operation theatre to be a big part of his life. He treats each member of his team as his family and shares everything with them. Inspired by an interview that he saw of the former CEO of JetBlue, he has trained his team to become efficient and to do their jobs perfectly so that he can start his next surgery immediately after completing the previous one. He considers himself to the pilot of the plane and his team to be the crew members. His team is the reason why he has been so successful in these surgeries since they take care of everything in the operating room without him having to worry about anything. Dr. David Samadi also urges people to invest in telesurgery and telemedicine technology as it will allow surgeons to perform many different kind of surgeries remotely and efficiently.

Dr. David Samadi Social Media: www.youtube.com/user/RoboticOncology

Treatment Center of America Using Top Notch Technology

The Cancer Treatment Centers of America is by far the most well respected set of treatment centers in America because of how well they conduct business and provide solutions for their visitors and patients. They strive to come up with ways to give their patients the respect and help they get so they can live their lives once again in the world. The best part about their company is how well they are trying to help their patients even more in the world of advanced technology. One thing they are capable of doing is creating new technology like the Clinical Pathways program.

Clinical Pathways is what this treatment center alongside two amazing companies in the health industry created to give patients the knowledge they needed. Things like updated supported data and other information regarding their current state of health is all shared. When engaged, this new technology can look deep into what a patient is dealing with at the moment and provide different custom generated options for their cancer to treat their health. Things like updates on what they need and also how much it costs could also inform the patient, so now the patient doesn’t have to end up choosing a treatment that is way out of their budget.

The Myctca.com Cancer Treatment Centers of America is here to give patients what they need and want, alongside the right advanced treatments that are best going to serve them for the future. In a world where cancer is tough to deal with, these five treatment centers are filled with hard working individuals who can help provide a patient with what they need so they can get back to their best possible health. There’s a long list of people who have relied on the team behind these companies, and they will vouch that they’re the best.

For more information follow CTCA on Facebook.

Clay Siegall may have found cure for cancer

Clay Siegall, the cancer innovator and founder of Seattle Genetics, has spent a lifetime searching for novel cancer therapies that someday may lead to what’s known in the business as the c word, a bona fide cure. With over 15 years as a researcher and nearly 20 as a CEO of his own firm, Dr. Siegall is one of the world’s foremost cancer experts and will be one of the key players to watch in the coming decades of cancer research.



A new therapy for an ancient scourge


Dr. Siegall was first drawn to cancer research when he was made aware for the first time, as a college student, of the barbaric and sometimes lethal treatments for many different types of cancer. Ranging from horrific, like the nausea-inducing and completely debilitating metal-based chemotherapies, to the ghastly, like the various radical surgical techniques which involve amputations and other grievous excisions, the orthodoxy of cancer treatment leaves the worst excesses of the Inquisition to want for brutality.


After working as a cancer researcher for 15 years, Dr. Siegall discovered a new class of drugs that promised an end to all that was diabolic about cancer treatment. These were called the antibody drug conjugates.


The principle behind them is startlingly simple. An antibody drug conjugate binds a cytotoxin, something that kills cells, to an antibody, which in this context is a kind of enzyme which binds to a particular molecule in the tumor. Once bound to the tumor, the antibody portion, which is conjugated, or linked, to the cytotoxin portion, releases the cytotoxin into the cellular environment, causing the immediate death of the cell in question and, in some cases, other neighboring cells.


What’s so revolutionary about these drugs is that they only target tumor cells. In the case of Seattle Genetics’ first FDA approved drug, Adcetris, the antibody targets a gene which is expressed specifically and only in Hodgkin lymphoma cells. Thus, there is no systemic release of the cytotoxin, as occurs in traditional chemotherapy. This reduces the side effects of treatment to almost nothing while vastly increasing the lethality to the malignancy.

Seattle Genetics Is Kicking Cancers Butt!

Cancer is a battle many people fight everyday. Both patients and families are effected by the physical, emotional and financial strains of the chronic condition. For years, the traditional form of cancer treatment has been through Chemotherapy. Chemotherapy, commonly known as chemo, is a cancer treatment that uses a combination of anti-cancer drugs to destroy cancer cells. While it is the most common form of cancer treatment, it is not the only option. Chemotherapy has a high probability of introducing harmful toxins to the body, and producing side effects rendering patients incapable of performing routine activities on their own. Being educated and informed on the side effects of chemotherapy, and the other options available could greatly improve the quality of life for cancer patients.


Co-founder of Biotechnology company Seattle Genetics Clay Siegall is committed to delivering alternative cancer treatment options to patients and their families. As an industry leader in antibody-drug conjugates, they have earned their mark at the top of innovative cancer treatment options. Unlike chemotherapy, ADCs target and kill cancer cells through the use of monoclonal antibodies, and harness the potential to enhance anti-tumor activity. Choosing an ADC treatment may also reduce the risk of toxic effects associated with traditional chemotherapy. ADCETRIS is the first ADC released by Seattle Genetics, with the help of Takeda Pharmaceutical Company. The new ADC is currently available in over 50 countries.

In an effort to reach more patients, Seattle Genetics is conducting a large scale clinical development program that will serve to assess the potency of the ACDs in regards to lymphoma and non-lymphoma patients. Through the development program, and their partnership with Takeda Pharmaceutical Company, Seattle Genetics received complete commercialization rights to ADCETRIS in the United States and Canada. When Seattle Genetics was founded, they had one goal. Cancer patients needed more options, and more education on their condition. With the introduction of ADCETRIS, slowly but surly, they are changing the world of cancer treatment, attacking one cell at a time.